

Index

A

Agency theory 15, 21, 48, 53, 99,
127, 141, 142, 145

B

Behavioral agency model 3, 23, 46,
99, 142–145

Big Pharma 80, 85, 88

Biotech 80, 87, 88, 98, 111

Blockbuster drugs 72, 80

Board of directors 48, 105, 109, 121,
123, 125, 142–144, 150

Bodies of practice 125

Bodies of science 126

C

CEO duality 48, 109, 112, 113, 115,
116, 120–122, 124, 125, 127,
128, 130

E

Exploitation/exploitative 76, 84, 87,
100, 102

Exploration/explorative 46, 54, 76,
84, 143, 152

F

Family board member(s) 89, 116,
123, 125, 126, 129, 143,
150–152

Family business 2, 3, 5, 10–15, 19,
22, 23, 44, 58, 82, 84, 97, 99,
102, 105, 109, 110, 120, 131,
144, 146

Family CEO 109, 112–116, 118,
120–122, 124–128, 130, 131,
149, 151

Family control 14, 24, 27, 29, 47,
51

- Family firm(s) 2–5, 10–15, 17–20, 23–26, 28–30, 42–47, 49–61, 79, 83, 86, 89, 96, 99, 102, 105, 108, 116, 117, 120, 122, 125, 130, 139, 140, 142–147, 149–152
- Family goal (s) 14
- Family governance 43, 53, 56, 109, 121, 123
- Family management 12, 27, 47–49, 51, 53, 59, 109, 126, 127, 141, 144, 152
- Family ownership 11, 26, 45, 48–51, 53, 59, 101, 105, 109, 112, 115–119, 121, 122, 124, 127–131, 141, 142, 145, 151
- Family supervision 109, 112–117, 119–122, 124–126, 128–132, 142, 143, 145, 146
- Forward citations 105, 107, 113, 127
- G**
- Generics 75, 86
- H**
- Human capital 14, 45, 50, 51
- I**
- Incentive(s) 4, 16–18, 45, 47–49, 56, 57, 61, 74, 85, 98, 100, 102, 110, 145, 146, 151
- Innovation basicness 107, 112–115, 118–120, 123–127, 131, 132
- Innovation input(s) 2, 44, 49, 54, 57, 58, 60, 61, 96, 97, 99, 100, 140, 144, 149
- Innovation orientation 52, 100, 144
- Innovation output(s) 4, 44, 49, 50, 53, 54, 60, 96, 100, 101, 130, 140, 141, 144, 145, 149, 150
- Innovation performance 42, 43, 50–53, 55, 59, 97–100, 106, 110, 112, 120, 121, 123, 127, 132, 140–142, 144–146, 149, 150
- Innovation scale 107, 112, 113, 115, 117–121, 132, 145, 149
- Innovation value 106–108, 112–115, 117–119, 123, 127, 129, 131
- Institutional framework 146, 147
- L**
- Long-term horizon 16
- Loss aversion 24–26, 100
- M**
- Market exclusivity 73, 74
- N**
- Nepotism 17, 28, 48, 56
- O**
- Open innovation 60, 72
- Ownership structure 10, 12, 18, 19, 105, 109, 114, 140
- P**
- Patent(s) 52, 54, 73, 74, 84, 104–108, 111, 113, 121, 123, 124, 127–130, 142, 143, 149
- Pharmaceutical industry 3, 4, 48, 72–76, 78–88, 101, 103–107,

111, 116, 121, 125–127, 129,
140, 146, 147
Pipeline 87, 111, 125

R

R&D 25, 44–49, 51, 54, 60, 72–74,
76, 78, 80, 81, 84–86, 89, 100,
110, 123, 140, 147, 151
Regulatory framework 88, 146, 147
Resource-based view 14, 15, 19, 52,
99, 141, 145
Risk aversion 4, 23, 26, 50, 82, 102,
125
Risk-taking 23, 25, 45, 51, 52, 59

S

Scientific citations 107, 113, 125
Socio-emotional wealth (SEW) 24,
46, 99, 143
Stewardship theory 3, 15, 21, 26, 30,
48, 52

T

Technological classes 105, 108, 114,
129
Technological scope 106, 108, 110,
112–115, 117–120, 123,
129–131, 144
Technology-intensity 147